Provided by Tiger Trade Technology Pte. Ltd.

ODDITY Tech Ltd.

14.49
+0.35002.48%
Post-market: 14.490.00000.00%16:19 EDT
Volume:761.29K
Turnover:10.97M
Market Cap:668.35M
PE:18.34
High:14.70
Open:14.12
Low:14.05
Close:14.14
52wk High:64.23
52wk Low:9.25
Shares:46.12M
Float Shares:28.59M
Volume Ratio:0.97
T/O Rate:2.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.7900
EPS(LYR):1.80
ROE:16.40%
ROA:3.99%
PB:2.24
PE(LYR):8.05

Loading ...

SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company

GlobeNewswire
·
1 hour ago

Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewswire
·
Sep 01

Oddity Tech CFO Lindsay Drucker Mann Disposes of 39,360 Common Shares Worth $587,688.94

Reuters
·
Sep 01

Oddity Tech Files Initial Beneficial Ownership Statement for Director Dave Scott Cohen

Reuters
·
Aug 29

Oddity Tech CFO Lindsay Drucker Mann Disposes of 3,493 Shares for $52,423.93

Reuters
·
Aug 28

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

GlobeNewswire
·
Aug 25

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage

GlobeNewswire
·
Aug 25

Oddity Tech Names Ex-Morgan Stanley IM Executive David S. Cohen Independent Director, Audit Committee Member

Reuters
·
Aug 21

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement

GlobeNewswire
·
Aug 20

Press Release: Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

Dow Jones
·
Aug 06

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals

GlobeNewswire
·
Aug 06

Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

GlobeNewswire
·
Aug 04

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody IND Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise

GlobeNewswire
·
Aug 03

Press Release: Radiopharm Theranostics Reports Business Update

Dow Jones
·
Jul 31

ODDITY Tech Shareholders Approve All Proposals at 2026 Annual Meeting

TIPRANKS
·
Jul 31

5 Microcap Software Stocks Expected to Soar by Triple Digits as the Companies' Sales Pop

Dow Jones
·
Jul 30

ODDITY to Announce Second Quarter 2026 Financial Results on September 9, 2026

GlobeNewswire
·
Jul 23

Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation

GlobeNewswire
·
Jul 21

Oddity Tech CFO Lindsay Drucker Mann Disposes of USD 1.65 Million in Common Shares

Reuters
·
Jul 01

Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)

GlobeNewswire
·
Jun 30